230 related articles for article (PubMed ID: 19450601)
1. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression.
Mandapathil M; Lang S; Gorelik E; Whiteside TL
J Immunol Methods; 2009 Jul; 346(1-2):55-63. PubMed ID: 19450601
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients.
Schuler PJ; Schilling B; Harasymczuk M; Hoffmann TK; Johnson J; Lang S; Whiteside TL
Eur J Immunol; 2012 Jul; 42(7):1876-85. PubMed ID: 22585562
[TBL] [Abstract][Full Text] [Related]
3. Extracorporeal photophoresis augments function of CD4+CD25+FoxP3+ regulatory T cells by triggering adenosine production.
Schmitt S; Johnson TS; Karakhanova S; Näher H; Mahnke K; Enk AH
Transplantation; 2009 Aug; 88(3):411-6. PubMed ID: 19667946
[TBL] [Abstract][Full Text] [Related]
4. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis.
Fletcher JM; Lonergan R; Costelloe L; Kinsella K; Moran B; O'Farrelly C; Tubridy N; Mills KH
J Immunol; 2009 Dec; 183(11):7602-10. PubMed ID: 19917691
[TBL] [Abstract][Full Text] [Related]
5. Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets.
Schuler PJ; Harasymczuk M; Schilling B; Lang S; Whiteside TL
J Immunol Methods; 2011 Jun; 369(1-2):59-68. PubMed ID: 21513715
[TBL] [Abstract][Full Text] [Related]
6. Functional and phenotypic characteristics of CD4+CD25highFoxp3+ Treg clones obtained from peripheral blood of patients with cancer.
Strauss L; Bergmann C; Whiteside TL
Int J Cancer; 2007 Dec; 121(11):2473-83. PubMed ID: 17691114
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of CD4
McRae JL; Chia JS; Pommey SA; Dwyer KM
Nephrology (Carlton); 2017 Jul; 22(7):505-512. PubMed ID: 27517975
[TBL] [Abstract][Full Text] [Related]
8. The abnormal function of CD39
Lu Y; Cheng L; Li F; Ji L; Shao X; Wu B; Zhan Y; Liu C; Min Z; Ke Y; Sun L; Chen H; Cheng Y
Ann Hematol; 2019 Aug; 98(8):1845-1854. PubMed ID: 31154474
[TBL] [Abstract][Full Text] [Related]
9. Characterization of regulatory T cells identified as CD4(+)CD25(high)CD39(+) in patients with active tuberculosis.
Chiacchio T; Casetti R; Butera O; Vanini V; Carrara S; Girardi E; Di Mitri D; Battistini L; Martini F; Borsellino G; Goletti D
Clin Exp Immunol; 2009 Jun; 156(3):463-70. PubMed ID: 19438599
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients.
Jie HB; Gildener-Leapman N; Li J; Srivastava RM; Gibson SP; Whiteside TL; Ferris RL
Br J Cancer; 2013 Nov; 109(10):2629-35. PubMed ID: 24169351
[TBL] [Abstract][Full Text] [Related]
11. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells.
Mandapathil M; Hilldorfer B; Szczepanski MJ; Czystowska M; Szajnik M; Ren J; Lang S; Jackson EK; Gorelik E; Whiteside TL
J Biol Chem; 2010 Mar; 285(10):7176-86. PubMed ID: 19858205
[TBL] [Abstract][Full Text] [Related]
12. Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype.
Dwyer KM; Hanidziar D; Putheti P; Hill PA; Pommey S; McRae JL; Winterhalter A; Doherty G; Deaglio S; Koulmanda M; Gao W; Robson SC; Strom TB
Am J Transplant; 2010 Nov; 10(11):2410-20. PubMed ID: 20977632
[TBL] [Abstract][Full Text] [Related]
13. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.
Strauss L; Bergmann C; Szczepanski M; Gooding W; Johnson JT; Whiteside TL
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4345-54. PubMed ID: 17671115
[TBL] [Abstract][Full Text] [Related]
14. Increased frequency and suppressive activity of CD127(low/-) regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement.
Drennan S; Stafford ND; Greenman J; Green VL
Immunology; 2013 Nov; 140(3):335-43. PubMed ID: 23826668
[TBL] [Abstract][Full Text] [Related]
15. Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer.
Schuler PJ; Harasymczuk M; Schilling B; Saze Z; Strauss L; Lang S; Johnson JT; Whiteside TL
Clin Cancer Res; 2013 Dec; 19(23):6585-96. PubMed ID: 24097865
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease.
Schulze Zur Wiesch J; Thomssen A; Hartjen P; Tóth I; Lehmann C; Meyer-Olson D; Colberg K; Frerk S; Babikir D; Schmiedel S; Degen O; Mauss S; Rockstroh J; Staszewski S; Khaykin P; Strasak A; Lohse AW; Fätkenheuer G; Hauber J; van Lunzen J
J Virol; 2011 Feb; 85(3):1287-97. PubMed ID: 21047964
[TBL] [Abstract][Full Text] [Related]
17. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression.
Borsellino G; Kleinewietfeld M; Di Mitri D; Sternjak A; Diamantini A; Giometto R; Höpner S; Centonze D; Bernardi G; Dell'Acqua ML; Rossini PM; Battistini L; Rötzschke O; Falk K
Blood; 2007 Aug; 110(4):1225-32. PubMed ID: 17449799
[TBL] [Abstract][Full Text] [Related]
18. Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis.
Grant CR; Liberal R; Holder BS; Cardone J; Ma Y; Robson SC; Mieli-Vergani G; Vergani D; Longhi MS
Hepatology; 2014 Mar; 59(3):1007-15. PubMed ID: 23787765
[TBL] [Abstract][Full Text] [Related]
19. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer.
Mandapathil M; Szczepanski MJ; Szajnik M; Ren J; Lenzner DE; Jackson EK; Gorelik E; Lang S; Johnson JT; Whiteside TL
Clin Cancer Res; 2009 Oct; 15(20):6348-57. PubMed ID: 19825957
[TBL] [Abstract][Full Text] [Related]
20. Human antigen-specific CD4⁺ CD25⁺ CD134⁺ CD39⁺ T cells are enriched for regulatory T cells and comprise a substantial proportion of recall responses.
Seddiki N; Cook L; Hsu DC; Phetsouphanh C; Brown K; Xu Y; Kerr SJ; Cooper DA; Munier CM; Pett S; Ananworanich J; Zaunders J; Kelleher AD
Eur J Immunol; 2014 Jun; 44(6):1644-61. PubMed ID: 24752698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
